Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene, Ethos Veterinary Health Collaborate on Pathogen Detection Testing

NEW YORK (GenomeWeb) – LexaGene announced today that it has partnered with Ethos Veterinary Health to test canine urine samples on LexaGene's LX6 prototype pathogen detection instrument.

Veterinarians at Ethos will send LexaGene clinically annotated urine samples for processing and pathogen detection on the LX6. The samples have been previously characterized using conventional technologies such as MALDI-TOF mass spectrometry at LexaGene's reference laboratory, the firm added.

LexaGene is currently developing the LX6 diagnostic tool as an open access, fully automated platform that allows end users to load real-time PCR assays. It will process six samples at a time and return results in around an hour, the firm said.

This collaboration "will allow our team to continue to fine-tune and perfect our pathogen detection prototype's testing capabilities," LexaGene CEO Jack Regan said in a statement. "This process is vital as we improve sensitivity to different isolates. We expect this to be a long-lasting collaboration as we work together to bring the best product possible to the veterinary market."

Financial terms of the deal were not disclosed.

In December, LexaGene closed a bought deal financing, raising gross proceeds of about $3.9 million. The company said it would use the funds to accelerate the deployment of its microfluidic technology, among other uses.